BG105654A - Полиморфни форми на телмизартан, метод за тяхнотополучаване и тяхната употреба за получаване на лекарство - Google Patents

Полиморфни форми на телмизартан, метод за тяхнотополучаване и тяхната употреба за получаване на лекарство

Info

Publication number
BG105654A
BG105654A BG105654A BG10565401A BG105654A BG 105654 A BG105654 A BG 105654A BG 105654 A BG105654 A BG 105654A BG 10565401 A BG10565401 A BG 10565401A BG 105654 A BG105654 A BG 105654A
Authority
BG
Bulgaria
Prior art keywords
polymorphic forms
telmizartan
medicine
treatment
relates
Prior art date
Application number
BG105654A
Other languages
English (en)
Other versions
BG65027B1 (bg
Inventor
Heinrich Schneider
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of BG105654A publication Critical patent/BG105654A/bg
Publication of BG65027B1 publication Critical patent/BG65027B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретението се отнася до полиморфна форма на 4'- [2-n-пропил-4-метил-6- (1-метилбензимидазол-2-ил) бензимидазол-1-илметил] бифенил-2-карбоксилна киселина (INN: телмизартан), по-специално до полиморфна форма В с формула@@Съединението има ендотермичен максимум при 183 20С, получен при термичен анализ чрез DSC. Изобретението се отнася и до смеси отполиморфни форми, до метод за получаване на телмизартан, съдържащ форма В, и до неговата употреба за получаване на лекарствено средство.
BG105654A 1999-01-19 2001-06-27 Полиморфни форми на телмизартан, метод за тяхнотополучаване и тяхната употреба за получаване на лекарство BG65027B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19901921A DE19901921C2 (de) 1999-01-19 1999-01-19 Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
PCT/EP2000/000065 WO2000043370A1 (de) 1999-01-19 2000-01-07 Polymorphe von telmisartan, verfahren zu deren herstellung und deren verwendung zur herstellung eines arzneimittels

Publications (2)

Publication Number Publication Date
BG105654A true BG105654A (bg) 2002-01-31
BG65027B1 BG65027B1 (bg) 2006-12-29

Family

ID=7894715

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105654A BG65027B1 (bg) 1999-01-19 2001-06-27 Полиморфни форми на телмизартан, метод за тяхнотополучаване и тяхната употреба за получаване на лекарство

Country Status (36)

Country Link
EP (1) EP1144386B1 (bg)
JP (1) JP4700813B2 (bg)
KR (1) KR100658959B1 (bg)
CN (1) CN1144790C (bg)
AR (1) AR035475A1 (bg)
AT (1) ATE252564T1 (bg)
AU (1) AU765081B2 (bg)
BG (1) BG65027B1 (bg)
BR (1) BR0007584A (bg)
CA (1) CA2352436C (bg)
CO (1) CO5150238A1 (bg)
CZ (1) CZ297412B6 (bg)
DE (2) DE19901921C2 (bg)
DK (1) DK1144386T3 (bg)
EA (1) EA003065B1 (bg)
EE (1) EE04344B1 (bg)
ES (1) ES2208265T3 (bg)
HK (1) HK1041485B (bg)
HR (1) HRP20010514B1 (bg)
HU (1) HU227401B1 (bg)
IL (2) IL143634A0 (bg)
MY (1) MY122755A (bg)
NO (1) NO319823B1 (bg)
NZ (1) NZ513528A (bg)
PE (1) PE20001362A1 (bg)
PL (1) PL211829B1 (bg)
PT (1) PT1144386E (bg)
RS (1) RS50044B (bg)
SA (1) SA99200838B1 (bg)
SK (1) SK285429B6 (bg)
TR (1) TR200102074T2 (bg)
TW (1) TWI280241B (bg)
UA (1) UA56358C2 (bg)
UY (1) UY25980A1 (bg)
WO (1) WO2000043370A1 (bg)
ZA (1) ZA200104771B (bg)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DE10153737A1 (de) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
IL162754A0 (en) * 2002-01-16 2005-11-20 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof
DE10314702A1 (de) 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
US7501448B2 (en) 2004-10-15 2009-03-10 Teva Pharmaceutical Industries, Ltd. Process for preparing telmisartan
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
SI2443094T1 (sl) 2009-06-19 2013-08-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo telmisartana
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
ITMI20102416A1 (it) * 2010-12-27 2012-06-28 Chemelectiva S R L Intermedio per la preparazione di un principio attivo e processo per la sua preparazione
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
JP6147546B2 (ja) * 2013-04-10 2017-06-14 株式会社トクヤマ 酢酸が低減されたテルミサルタンａ型結晶の製造方法
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
JP6275596B2 (ja) * 2014-09-03 2018-02-07 株式会社トクヤマ テルミサルタンのアンモニウム塩の製造方法
JP5871294B1 (ja) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
KR20170012703A (ko) 2015-07-22 2017-02-03 대원제약주식회사 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
KR102044223B1 (ko) * 2016-09-12 2019-11-13 성균관대학교산학협력단 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법
CN106749037B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用
CN106749036B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用
NZ759782A (en) 2017-07-07 2023-06-30 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
CN109851562A (zh) * 2019-01-30 2019-06-07 浙江省食品药品检验研究院 一种替米沙坦晶体及其制备方法
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs
EP4373474A1 (en) 2021-07-22 2024-05-29 KRKA, D.D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202541793A (zh) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5139114A (en) * 1991-03-18 1992-08-18 Abex Corporation Visible brake block wear indicator

Also Published As

Publication number Publication date
CN1144790C (zh) 2004-04-07
PE20001362A1 (es) 2000-12-15
DE19901921C2 (de) 2001-01-04
TWI280241B (en) 2007-05-01
HUP0105148A2 (hu) 2002-07-29
EA003065B1 (ru) 2002-12-26
DK1144386T3 (da) 2004-01-12
HRP20010514A2 (en) 2002-08-31
KR20010101552A (ko) 2001-11-14
HU227401B1 (en) 2011-05-30
AU765081B2 (en) 2003-09-11
DE50004150D1 (de) 2003-11-27
CO5150238A1 (es) 2002-04-29
EE200100375A (et) 2002-10-15
AU2288100A (en) 2000-08-07
NO20013560D0 (no) 2001-07-18
DE19901921A1 (de) 2000-08-03
IL143634A (en) 2006-10-05
CZ20012634A3 (cs) 2001-10-17
UA56358C2 (uk) 2003-05-15
PL211829B1 (pl) 2012-06-29
UY25980A1 (es) 2001-08-27
PT1144386E (pt) 2004-03-31
NO319823B1 (no) 2005-09-19
EA200100730A1 (ru) 2002-02-28
CA2352436A1 (en) 2000-07-27
WO2000043370A1 (de) 2000-07-27
SK285429B6 (sk) 2007-01-04
RS50044B (sr) 2008-11-28
ES2208265T3 (es) 2004-06-16
KR100658959B1 (ko) 2006-12-19
AR035475A1 (es) 2004-06-02
HK1041485A1 (en) 2002-07-12
BG65027B1 (bg) 2006-12-29
ATE252564T1 (de) 2003-11-15
CN1336920A (zh) 2002-02-20
BR0007584A (pt) 2001-11-06
SK10202001A3 (sk) 2001-12-03
CZ297412B6 (cs) 2006-12-13
EE04344B1 (et) 2004-08-16
JP2002535315A (ja) 2002-10-22
MY122755A (en) 2006-05-31
IL143634A0 (en) 2002-04-21
HUP0105148A3 (en) 2003-01-28
CA2352436C (en) 2010-03-23
NZ513528A (en) 2003-08-29
SA99200838B1 (ar) 2006-03-06
NO20013560L (no) 2001-09-18
JP4700813B2 (ja) 2011-06-15
EP1144386A1 (de) 2001-10-17
ZA200104771B (en) 2002-12-02
TR200102074T2 (tr) 2001-12-21
EP1144386B1 (de) 2003-10-22
PL349425A1 (en) 2002-07-29
YU51101A (sh) 2004-05-12
HRP20010514B1 (en) 2010-01-31
HK1041485B (zh) 2004-10-08

Similar Documents

Publication Publication Date Title
YU51101A (sh) Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka
DK3100727T3 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
KR910007927A (ko) 축합 이미다졸 유도체 및 이의 제조방법
CY1109490T1 (el) Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων
MX2014009931A (es) Farmacos antivirales para el tratamiento de la infeccion por arenavirus.
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
TR200200648T2 (tr) Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri.
BR0114092A (pt) Guanididas de ácido cinámico substituìdas, processos para a sua preparação, sua aplicação como medicamento bem como o medicamento contendo as mesmas
ZA200206497B (en) Androgen receptor suppressors in the therapy and diagnosis of prostate cancer alopecia and other hyper-androgenic syndromes.
CA2518115A1 (en) Nucleotide phosphoramidates as anticancer agents
MY129741A (en) Crystalline form of telmisartan sodium
RU2009144538A (ru) Новые циклические пептидные соединения
DE2160946C3 (de) aminocarbonsäureamide und diese Verbindungen enthaltende Arzneimittel
AU2020341464A1 (en) Methods of treating epilepsy using the same
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
MXPA05013856A (es) Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad.
RU2003134010A (ru) 5-замещенные-2-арилпиридины в качестве модуляторов crf1
CA2422916A1 (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
MA29258B1 (fr) Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1837329A4 (en) NEW HETEROARYL DERIVATIVE
SE9903611D0 (sv) Novel compounds III
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
DE69910738D1 (de) Fungizide zusammensetzung enthaltend ein n-benzoyl-n'-phenyl-harnstoff derivat